Alx Oncology Holdings Inc (ALXO) is a clinical-stage immuno-oncology company that develops therapies to treat cancer. The company is focused on developing therapies that target CD47, a molecule that acts as a "don't eat me" signal to prevent the immune system from attacking cancer cells. ALXO's lead candidate, ALX148, is an investigational CD47-blocking therapeutic that has shown promising results in preclinical and clinical studies.
ALXO is also developing ALX0361, a fusion protein that combines a potent PD-1 checkpoint inhibitor with a CD80 co-stimulatory agonist. This approach is designed to both block the PD-1 pathway, which can suppress the immune response to cancer, and activate the CD28 pathway, which can enhance the immune response to cancer.
As of September 2021, ALXO has ongoing clinical trials for both ALX148 and ALX0361, with several Phase 1 and Phase 2 trials evaluating the safety and efficacy of these therapies in various cancer indications. ALXO is also exploring the potential of CD47-targeting therapies in combination with other immuno-oncology agents, such as PD-1/PD-L1 inhibitors and chemotherapy.
ALXO went public in July 2020 and is listed on the Nasdaq Global Select Market under the ticker symbol "ALXO." The company is headquartered in Burlingame, California.
|
